Enact Holdings, Inc. (ACT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since ...

Financial giants have made a conspicuous bullish move on Vistra. Our analysis of options history for Vistra (NYSE:VST) revealed 39 unusual trades.Delving into the details, we found 43% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $757,098, and 30 were calls, valued at $1,576,617.Expected Price MovementsAfter evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band b ...

It's time for the big three. Three stocks, three charts, three trades. Rick Dat will take us through the charts. Here to take us through the trades today, Don Kaufman, the co-founder at TheOT Trade.Great to have you both with us. Don, we'll start the same way we always do. Big picture thought on the markets.I did think we might see a bit more reaction to the State of the Union last night, but a pretty measured response this morning. >> Yeah, you know what. Uh, yeah, that's that's actually a great place to s ...

四大利好引爆！21只小金属龙头涨停，金银再迎大涨 在A股市场里，资源类板块向来是行情的"硬通货担当"，每当利好扎堆、资金共振，小金属与贵金属总能率先点燃赚钱效应。 2026年2月25日，A股迎来四大利好集中落地，小金属板块彻底爆发，21只细分龙头齐刷刷封死涨停板，稀土、钨、锗、钛等核心品种全线走强；与 此同时，国际黄金、白银价格同步大幅拉升，国内贵金属板块跟涨冲高，资源主线成为当日盘面最亮眼的主角。 一、权威数据实锤：2月25日资源板块全线爆发 本文所有数据均来自同花顺、东方财富、上海黄金交易所、沪深交易所官方平台，2026年2月25日收盘真实可查，无任何杜撰内容。小金属概念板块 当日大涨4.00%，主力资金净流入140.34亿元，板块内154只个股上涨，21只细分龙头强势封板，东方钽业、华锡有色、云南锗业、安宁股份、中钨 高新、章源钨业、北方稀土等标的牢牢封住涨停，成为市场核心领涨力量。 贵金属板块同步走强，伦敦银现暴涨4.00%，报价90.703美元/盎司；沪银主连大涨4.57%，收报23029元/千克；伦敦金现站稳5186.1美元/盎司，涨幅 0.77%，黄金白银携手刷新阶段高位，全球资金涌入贵金属避险 ...

If there is one thing the 2026 State of the Union proved, it is that President Donald Trump remains the only person capable of turning a formal constitutional requirement into a four-hour marathon of populist giveaways and legal grievances. While the speech was officially the longest in American history—clocking in at a duration that suggests the President is being paid by the word—the stock market spent the evening doing what it does best when faced with “unpredictable” policy shifts: twitching nervously a ...

Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Exact name of registrant as specified in its charter) (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-19514 Gulfport Energy Corporation (State or ot ...

Financial Data and Key Metrics Changes - Trinity Capital achieved record net investment income of $144 million or $2.08 per share in 2025, with a 15% increase in Q4 net investment income to $40 million compared to the previous year [3][4] - The company's net asset value (NAV) grew 10% quarter-over-quarter to a record $1.1 billion, with a 33% year-over-year increase [5][16] - Total investment income for Q4 was $83 million, reflecting a 17.5% year-over-year increase, and the effective yield remained strong at 15.2% [15][16] Business Line Data and Key Metrics Changes - The managed funds business saw significant growth, with $1.5 billion in fundings and $2.1 billion in commitments for the year [4][6] - The breakdown of Q4 fundings included 27% to sponsor finance, 25% to equipment financing, 20% to life sciences, 15% to tech lending, and 13% to asset-backed lending [20] Market Data and Key Metrics Changes - The company maintained strong credit quality, with non-accruals at less than 1% of the portfolio at fair value [4][19] - Portfolio companies collectively raised over $7.8 billion in equity during 2025, indicating strong access to capital [19] Company Strategy and Development Direction - Trinity Capital is focused on building a diversified platform with five complementary verticals, including sponsor finance, equipment finance, tech lending, asset-based lending, and life sciences [12][14] - The company is strategically positioned to capitalize on opportunities in the market, particularly in the software sector, while maintaining a disciplined underwriting approach [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate market volatility and capitalize on opportunities, particularly in the lower middle market software sector [25][36] - The company anticipates continued strong performance driven by its diversified pipeline and disciplined investment strategy [14][21] Other Important Information - Trinity Capital transitioned to a monthly dividend of $0.17 per share starting January 2026, maintaining the same aggregate quarterly payout [15] - The company raised $95 million through its equity ATM program during Q4, contributing to a strong capital base [16] Q&A Session Summary Question: Opportunities in Software Loans - Management acknowledged the potential to capitalize on turmoil in the software sector and indicated a willingness to convert some loans to equipment finance loans for better risk-adjusted returns [23][25] Question: Portfolio Concerns - Management stated that they remain focused on industries with disruptive technology and strong capital backing, and they will continue to adapt their investment strategy as market conditions evolve [30][32] Question: Strategic Opportunities Amid Volatility - Management confirmed that they are prepared to be opportunistic in a volatile market, leveraging their liquidity to take advantage of less competitive conditions [36][37] Question: Fund Management Business Growth - Management expressed optimism about the growth of their third-party asset management business, anticipating increased interest from investors seeking diversification [41][42] Question: Portfolio Capital Raising - Management noted that portfolio companies are accessing capital through various means, including public markets and private equity sponsors, indicating a robust VC market [56][58]

Summary of Oric Pharmaceuticals FY Conference Call Company Overview - **Company**: Oric Pharmaceuticals (NasdaqGS:ORIC) - **Industry**: Clinical stage oncology - **Focus Areas**: Prostate cancer, lung cancer, and breast cancer [2][3] Key Programs 1. **Rinzimetostat (ORIC-944)**: - Allosteric PRC2 inhibitor targeting prostate cancer in combination with AR inhibitors (apalutamide and darolutamide) [2][3] - Phase III study expected to start in the first half of 2026 [3][4] - Early clinical data shows promising PSA response rates and favorable safety profile compared to Pfizer's data [5][17] 2. **Enosertinib**: - EGFR inhibitor with high potency on exon 20 and PAK mutations [3][43] - Demonstrated 100% overall response rate in patients with measurable disease, including those with untreated brain metastases [43] Market Opportunity - **Prostate Cancer**: - Large patient population with significant unmet needs; over $11 billion in sales for ARPi inhibitors last year [23][24] - Potential to reverse resistance to current therapies and extend treatment duration [24][25] - **Lung Cancer**: - High prevalence of CNS metastases in lung cancer patients, making CNS activity a critical differentiator for enosertinib [43][44] Competitive Landscape - **Rinzimetostat vs. Mevrometostat**: - Rinzimetostat is positioned as a potentially best-in-class PRC2 inhibitor with better drug properties, including solubility and half-life [11][12] - Early data suggests lower rates of gastrointestinal and hematological toxicities compared to competitors [17] - **Enosertinib's Differentiation**: - Focus on CNS activity and less off-target toxicities compared to competitors [43][44] Upcoming Milestones - **Rinzimetostat**: - Q1 update with data from 20-25 patients expected, focusing on PSA50, PSA90, safety, and tolerability [38][39] - Phase III study initiation in the first half of 2026 [3][38] - **Enosertinib**: - Continued evaluation of monotherapy and combination strategies, with updates expected in the second half of 2026 [48][49] Investor Considerations - The stock's performance is closely tied to the outcomes of the MEVPRO-1 study and the company's own data releases [53][56] - Rinzimetostat is viewed as a potential blockbuster if it demonstrates differentiation in safety and efficacy [58] Conclusion Oric Pharmaceuticals is strategically positioned in the oncology space with promising drug candidates targeting significant unmet needs in prostate and lung cancers. The upcoming data releases and competitive positioning will be critical for investor confidence and stock performance moving forward.

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.We live in an era of instant gratification, and that parlays into expectations for quick returns on growth stocks. That notion comes with fallacies, as the r ...

Core Insights - The rapid appreciation of Algorhythm Holdings' shares is driven by investor excitement around AI applications in domestic freight, but Warp cautions that stock volatility does not equate to real freight efficiency [1] - Warp emphasizes that true freight innovation requires redesigning infrastructure rather than merely adding automation to existing models [1] Company Overview - Warp operates a digital freight network with 15,000 carriers, coordinating cross-docks, warehouses, and retail destinations across the U.S. [2] - The company collaborates with major retailers, including Walmart, to achieve measurable performance improvements in middle-mile and store-delivery networks [2] - Warp has successfully moved over a million shipments in the past four years [2] Technology and Operations - Warp's AI agent infrastructure functions within a unified execution system, allowing for coordinated actions in load matching, appointment scheduling, shipment monitoring, exception resolution, and billing reconciliation [3] - Unlike traditional operators, Warp dynamically adjusts capacity across various vehicle types based on changing conditions, optimizing shipment timing and eliminating underutilized miles [4] - The system not only automates tasks but also continuously reconfigures the network to enhance efficiency [4] Performance Metrics - Warp reports significant operational improvements, including a 12% to 20% reduction in cost per pallet, a 15% to 25% reduction in damage rates, and 1 to 2 day improvements in transit times on regional lanes [6] - The company also achieves higher shipment volume per employee compared to traditional freight operators [6] Strategic Focus - Warp is committed to expanding its national cross-dock footprint and enhancing its AI-enabled execution platform [5]